Add a Calcium Channel Blocker (CCB)
The most appropriate next step is to add a dihydropyridine calcium channel blocker (such as amlodipine 5-10 mg daily) to your current regimen. This patient is on triple therapy but lacks a CCB, which is a critical component of the standard treatment algorithm for uncontrolled hypertension.
Current Regimen Analysis
Your patient is currently taking:
- Losartan 100 mg (ARB - maximized)
- Triamterene-HCTZ 37.5-25 mg (potassium-sparing diuretic + thiazide)
- Metoprolol 100 mg (beta-blocker)
With a BP of 146/91 mmHg, this represents uncontrolled hypertension despite triple therapy.
Why Add a CCB?
The 2020 International Society of Hypertension guidelines 1 provide a clear algorithmic approach for non-Black patients with uncontrolled hypertension:
- Step 1: ACE inhibitor/ARB (✓ completed - losartan 100 mg)
- Step 2: Add CCB (← you are here)
- Step 3: Increase to full dose
- Step 4: Add thiazide/thiazide-like diuretic (✓ already present)
- Step 5: Add spironolactone or alternatives
The patient has an ARB and diuretic but is missing the CCB, which is a cornerstone of triple therapy. The 2024 ESC guidelines 2 similarly recommend the combination of RAS blocker + CCB + diuretic as the standard triple-combination approach.
Specific Recommendation
Add amlodipine 5 mg daily, with titration to 10 mg if needed after 2-4 weeks 1, 3, 2. Amlodipine is preferred because:
- Once-daily dosing improves adherence
- Well-tolerated in combination with ARBs and diuretics
- Strong evidence base for cardiovascular outcomes 4
Important Caveats About Current Regimen
The Beta-Blocker Issue
Metoprolol is not a first-line agent for uncomplicated hypertension in this context 5. Beta-blockers are not preferred initial therapy and are less effective than other first-line agents 6. However, do not discontinue it yet - first optimize with the CCB addition. If BP remains uncontrolled after adding the CCB, consider whether the patient has a compelling indication for the beta-blocker (coronary disease, heart failure, post-MI, atrial fibrillation). If not, the beta-blocker could potentially be discontinued in favor of more effective agents.
The Triamterene-HCTZ Consideration
While triamterene does provide additional BP lowering beyond HCTZ alone 7, the current dose (37.5-25 mg) could potentially be optimized. However, address the missing CCB first before making other changes.
Target Blood Pressure
Your target should be <130/80 mmHg 1, 3, 1. The 2020 ISH guidelines emphasize achieving this target within 3 months of treatment initiation.
Monitoring Plan
- Recheck BP in 2-4 weeks after adding the CCB
- If BP remains ≥130/80 mmHg, increase amlodipine to 10 mg daily
- Monitor for peripheral edema (common CCB side effect)
- Reassess the entire regimen if BP remains uncontrolled on ARB + CCB + diuretic + beta-blocker
If Still Uncontrolled After CCB Addition
If BP remains elevated after optimizing the CCB dose, the next step per guidelines 1, 3, 2 would be to add spironolactone 25 mg daily (if potassium <4.5 mmol/L and eGFR adequate). At that point, also reconsider whether the metoprolol is necessary or could be replaced with spironolactone.
Key Pitfall to Avoid
Do not add a fourth agent before ensuring you have the optimal triple combination (ARB + CCB + diuretic). Many patients are on suboptimal combinations that include beta-blockers when they should have CCBs as part of their core regimen 1, 5, 2.